Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

The routine incorporation of NPM1, FLT3 and perhaps CEBPA-DM mutational testing can now be strongly recommended in addition to a standard karyotype evaluation. Patients with normal cytogenetics ...

to predict post-transplant relapse and survival compared to flow cytometry in patients with FLT3-ITD or NPM1 mutated AML. The current collection of manuscripts presents additional original data ...

The authors recommend that newly diagnosed patients with AML should be screened for NPM1, FLT3, and CEBPA mutations, as the data from such analyses provide important prognostic information and may ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

We are preparing to file a supplemental new drug application or sNDA next quarter that could expand the indicated population for Revuforj into mutant NPM1 AML around the end of the year.